Universität zu Köln

Frahm, Niklas ORCID: 0000-0002-4655-774X, Fneish, Firas, Ellenberger, David, Flachenecker, Peter, Paul, Friedemann, Warnke, Clemens ORCID: 0000-0002-3510-9255, Kleinschnitz, Christoph ORCID: 0000-0002-1650-8875, Parciak, Tina, Krefting, Dagmar ORCID: 0000-0002-7238-5339, Hellwig, Kerstin, Haas, Judith, Rommer, Paulus S., Stahmann, Alexander and Zettl, Uwe K. (2022). Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry. Neurol. Ther., 11 (1). S. 319 - 337. LONDON: SPRINGER LONDON LTD. ISSN 2193-6536

Full text not available from this repository.

Abstract

Introductions Therapy switches in patients with multiple sclerosis (MS) receiving treatment with fingolimod occur frequently in clinical practice but are not well represented in real-world data. The aim of this study was to identify and characterize treatment switches and reveal sociodemographic/clinical changes over time in fingolimod-treated people with MS (PwMS). Methods Data on 2536 fingolimod-treated PwMS extracted from the German MS Registry during different time periods were analyzed (2010-2019). Results Overall, 28.3% of PwMS were treatment-naive before fingolimod initiation. Interferon beta (30.7%) was the most common pre-fingolimod treatment. Ocrelizumab (19.8%) was the most frequent subsequent treatment in the 944 patients on fingolimod who switched. Between 2010 and 2019, median disease duration at fingolimod initiation decreased from 8.5 to 7.1 years (p < 0.001), and patients taking fingolimod for >= 1 year after treatment initiation decreased from 89.6 to 80.5% (p < 0.001). Females (p < 0.001) and young patients (p = 0.003) showed a shorter time on fingolimod. The most frequent reason for switching was disease activity (relapse/MRI) despite treatment. The annualized relapse rate increased from 0.37 in patients on fingolimod to 0.47 after treatment cessation, decreasing to 0.19 after treatment with a subsequent disease-modifying drug (DMD) was initiated. Conclusion Treatment switches from fingolimod to subsequent DMDs currently occur after shorter treatment durations than 10 years ago, possibly due to the growing treatment spectrum. Planning adequate washout periods is essential and should be done on an individualized basis.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Frahm, Niklas UNSPECIFIED orcid.org/0000-0002-4655-774X UNSPECIFIED Fneish, Firas UNSPECIFIED UNSPECIFIED UNSPECIFIED Ellenberger, David UNSPECIFIED UNSPECIFIED UNSPECIFIED Flachenecker, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Paul, Friedemann UNSPECIFIED UNSPECIFIED UNSPECIFIED Warnke, Clemens UNSPECIFIED orcid.org/0000-0002-3510-9255 UNSPECIFIED Kleinschnitz, Christoph UNSPECIFIED orcid.org/0000-0002-1650-8875 UNSPECIFIED Parciak, Tina UNSPECIFIED UNSPECIFIED UNSPECIFIED Krefting, Dagmar UNSPECIFIED orcid.org/0000-0002-7238-5339 UNSPECIFIED Hellwig, Kerstin UNSPECIFIED UNSPECIFIED UNSPECIFIED Haas, Judith UNSPECIFIED UNSPECIFIED UNSPECIFIED Rommer, Paulus S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Stahmann, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Zettl, Uwe K. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-692341
DOI:	10.1007/s40120-021-00320-w
Journal or Publication Title:	Neurol. Ther.
Volume:	11
Number:	1
Page Range:	S. 319 - 337
Date:	2022
Publisher:	SPRINGER LONDON LTD
Place of Publication:	LONDON
ISSN:	2193-6536
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language Clinical Neurology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/69234